Vaxcyte Prices $1 Billion Offerings of Stock, Prefunded Warrants, 2032 Notes

MT newswire2026/10/07 08:08

04:08 AM EDT, 10/07/2026 (MT Newswires) -- Vaxcyte (PCVX) has priced concurrent public offerings of common stock, pre-funded warrants and convertible senior notes due 2032, the company said late Tuesday. The common stock and pre-funded warrants offering is expected to generate about $500 million in gross proceeds, while the convertible notes offering is expected to generate another $500 million, Vaxcyte said. The stock offering consists of 7.41 million shares at $64 each and pre-funded warrants to purchase 400,000 shares at $63.999 each. Underwriters have a 30-day option to purchase up to an additional 1.17 million shares and $75 million of notes, the company said. Net proceeds will be used to fund clinical development of Vaxcyte's pneumococcal vaccine programs, including VAX-31, manufacturing expansion, research and development, and general corporate purposes, the company said. The offerings are expected to close Friday, subject to customary closing conditions.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.